Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Atkinson, Victoria"'
Autor:
Kennedy OJ; University of Manchester, Manchester, United Kingdom; Christie NHS Foundation Trust, Manchester, United Kingdom., Glassee N; EORTC Headquarters, Brussels, Belgium., Kicinski M; EORTC Headquarters, Brussels, Belgium., Blank CU; Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands., Long GV; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Atkinson VG; Princess Alexandra Hospital, Brisbane, QLD, Australia., Dalle S; Hospices Civils de Lyon Cancer Institute, Lyon, France., Haydon AM; Alfred Hospital, Melbourne, VIC, Australia., Meshcheryakov A; NN Blokhin Cancer Research Center, Moscow, Russian Federation., Khattak A; Fiona Stanley Hospital & Edith Cowan University, Perth, WA, Australia., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia., Sandhu S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Larkin J; Royal Marsden Hospital, London, United Kingdom., Puig S; Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, Spain & Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain., Ascierto PA; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Schadendorf D; University Hospital Essen, Essen, German Cancer Consortium, Partner Site Essen & University Alliance Ruhr Research Center One Health, Essen, Germany., Boers-Sonderen M; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands., Giacomo AMD; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., van den Eertwegh AJM; Amsterdam University Medical Center, location VUMC, Amsterdam, Netherlands., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Gutzmer R; Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Minden, Germany., Jamal R; Centre Hospitalier de l'Université de Montréal (CHUM), Centre de recherche du CHUM, Montreal, QC, Canada., van Akkooi ACJ; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Gandini S; IEO, European Institute of Oncology IRCCS, Milan, Italy., Buhrer E; EORTC Headquarters, Brussels, Belgium., Suciu S; EORTC Headquarters, Brussels, Belgium., Robert C; Gustave Roussy and Paris-Saclay University, Villejuif, France., Eggermont AMM; Princess Máxima Center and University Medical Center Utrecht, Utrecht, Netherlands; Comprehensive Cancer Center Munich, Technical University Munich & Ludwig Maximiliaan University, Munich, Germany., Mandala M; University of Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy., Lorigan P; Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Valpione S; Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, United Kingdom; Cancer Research UK National Biomarker Centre, Manchester, UK. Electronic address: sara.valpione@nhs.net.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Apr; Vol. 201, pp. 113585. Date of Electronic Publication: 2024 Feb 01.
Autor:
Weber JS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. Electronic address: Jeffrey.Weber@nyulangone.org., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, NSW, Australia., Khattak A; Hollywood Private Hospital, Perth, WA, Australia; Edith Cowan University, Perth, WA, Australia., Meniawy T; Saint John of God Subiaco Hospital, Subiaco, WA, Australia., Ansstas G; Washington University School of Medicine, St Louis, MO, USA., Taylor MH; Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Kim KB; California Pacific Medical Center Research Institute, San Francisco, CA, USA., McKean M; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Faries M; The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA., Tran TT; Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, USA., Cowey CL; Texas Oncology PA, Dallas, TX, USA., Pecora A; Hackensack University Medical Center, Hackensack, NJ, USA., Shaheen M; The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Segar J; University of Arizona, Tucson, AZ, USA., Medina T; University of Colorado Cancer Center, Aurora, CO, USA., Atkinson V; Princess Alexandra Hospital, Brisbane, QLD, Australia., Gibney GT; Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA., Luke JJ; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Thomas S; Orlando Health Kuhl Avenue, Orlando, FL, USA., Buchbinder EI; Dana-Farber Cancer Institute, Boston, MA, USA., Healy JA; Merck & Co, Rahway, NJ, USA., Huang M; Merck & Co, Rahway, NJ, USA., Morrissey M; Moderna, Cambridge, MA, USA., Feldman I; Moderna, Cambridge, MA, USA., Sehgal V; Moderna, Cambridge, MA, USA., Robert-Tissot C; Moderna, Cambridge, MA, USA., Hou P; Moderna, Cambridge, MA, USA., Zhu L; Moderna, Cambridge, MA, USA., Brown M; Moderna, Cambridge, MA, USA., Aanur P; Moderna, Cambridge, MA, USA., Meehan RS; Moderna, Cambridge, MA, USA., Zaks T; Moderna, Cambridge, MA, USA.
Publikováno v:
Lancet (London, England) [Lancet] 2024 Feb 17; Vol. 403 (10427), pp. 632-644. Date of Electronic Publication: 2024 Jan 18.
Autor:
Hepner A; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Instituto do Cancer do Estado de Sao Paulo, SP, Brazil., Versluis JM; Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands., Wallace R; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia., Allayous C; Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France., Brown LJ; Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia., Trojaniello C; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Gerard CL; Precision Oncology Center Oncology department, Lausanne University Hospital CHUV, Lausanne, Switzerland., Jansen YJ; Department of Thoracic Surgery, University Hospitals Leuven, Leuven 3000, Belgium., Bhave P; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Alfred Health, Melbourne, Australia., Neyns B; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Haydon A; Department of Medical Oncology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia., Michielin O; Precision Oncology Center Oncology department, Lausanne University Hospital CHUV, Lausanne, Switzerland., Mangana J; University Hospital Zürich, Zürich, Switzerland., Klein O; Olivia Newton-John Cancer Centre and Austin Health, Melbourne, Australia., Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA., Warner AB; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., McQuade JL; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carlino MS; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zimmer L; Department of Dermatology, University Hospital Essen, Essen, Germany., Lebbe C; Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville TN, USA., Sandhu S; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia; University of Melbourne, Melbourne, Australia., Atkinson V; University of Queensland and Princess Alexandra and Greenslopes Private Hospital, Brisbane, Australia., Blank CU; Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands; Leiden University Medical Center (LUMC), Leiden, the Netherlands., Lo SN; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, NSW, Australia. Electronic address: alexander.menzies@sydney.edu.au.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jan; Vol. 196, pp. 113441. Date of Electronic Publication: 2023 Nov 20.
Autor:
Thompson JR; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. jake.thompson@sydney.edu.au.; Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, Wollstonecraft, Sydney, NSW, 2065, Australia. jake.thompson@sydney.edu.au., Fu H; Department of Cancer Services, Princess Alexandra Hospital, University of Queensland, Woolloongabba, QLD, Australia., Saw RPM; Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, Wollstonecraft, Sydney, NSW, 2065, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Sherman KA; School of Psychological Sciences, Macquarie University, Macquarie Park, NSW, Australia., Beedle V; Melanoma Patients Australia, Varsity Lakes, QLD, Australia., Atkinson V; Department of Cancer Services, Princess Alexandra Hospital, University of Queensland, Woolloongabba, QLD, Australia., Boyle F; Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, Wollstonecraft, Sydney, NSW, 2065, Australia.; Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, North Sydney, NSW, Australia., O'Sullivan NA; Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, Wollstonecraft, Sydney, NSW, 2065, Australia., Martin LK; Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, Wollstonecraft, Sydney, NSW, 2065, Australia.; Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Bartula I; Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, Wollstonecraft, Sydney, NSW, 2065, Australia.
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2023 Dec; Vol. 32 (12), pp. 3531-3545. Date of Electronic Publication: 2023 Jul 31.
Autor:
Goodman RS; Vanderbilt University School of Medicine, Nashville, TN, USA., Di Guardo L; Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Milano Province, Italy., Maurichi A; Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Milano Province, Italy., Kirwin B; Department of Medical Oncology, Melanoma Institute of Australia, The University of Sydney, Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Khattak A; Department of Medical Oncology, Fiona Stanley Hospital, Edith Cowan University, Perth, WA, Australia., Vanella V; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Napoli Province, Italy., Lee J; Department of Medical Oncology, Blacktown and Westmead Hospitals, Sydney, New South Wales, Australia., Lawless A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Czapla J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Spagnoletti A; Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Milano Province, Italy., Ambrosini M; Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Milano Province, Italy., Livingstone E; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, North Rhine Westphalia, Germany., Long GV; Department of Medical Oncology, Melanoma Institute of Australia, The University of Sydney, Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Sullivan RJ; Division of Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Carlino MS; Department of Medical Oncology, Blacktown and Westmead Hospitals, Sydney, New South Wales, Australia; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Atkinson V; University of Queensland, Princess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, QLD, Australia., Trojanello C; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Napoli Province, Italy., Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Napoli Province, Italy., Schadendorf D; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, North Rhine Westphalia, Germany., Warburton L; Department of Medical Oncology, Fiona Stanley Hospital, Edith Cowan University, Perth, WA, Australia., Menzies AM; Department of Medical Oncology, Melanoma Institute of Australia, The University of Sydney, Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Santinami M; Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Milano Province, Italy., Johnson DB; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: douglas.b.johnson@vumc.org.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 194, pp. 113354. Date of Electronic Publication: 2023 Sep 22.
Autor:
Mallardo D; Melanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola, 53, 80131, Naples, Italy., Woodford R; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Zimmer L; Department of Dermatology, University Hospital Essen, NCT-West, German Cancer Consortium, Partner Site Essen and University Alliance Ruhr, Research Center One Health, Essen, Germany., Williamson A; Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK., Ramelyte E; Department of Dermatology, University of Zurich, Zurich, Switzerland., Dimitriou F; Department of Dermatology, University of Zurich, Zurich, Switzerland., Wicky A; Department of Oncology, Precision Oncology Center, Lausanne University Hospital, Rue du Bugnon 21, 1011, Lausanne, Switzerland., Wallace R; Peter MacCallum Cancer Centre, Melbourne, Australia., Mallardo M; Melanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola, 53, 80131, Naples, Italy., Cortellini A; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W120HS, UK.; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Biomedico, Rome, Italy., Budillon A; Scientific Director, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Atkinson V; Greenslopes Private Hospital, University of Queensland QLD, Greenslopes, Australia., Sandhu S; Peter MacCallum Cancer Centre, Melbourne, Australia., Olivier M; Department of Oncology, Precision Oncology Center, Lausanne University Hospital, Rue du Bugnon 21, 1011, Lausanne, Switzerland., Dummer R; Department of Dermatology, University of Zurich, Zurich, Switzerland., Lorigan P; Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK., Schadendorf D; Department of Dermatology, University Hospital Essen, NCT-West, German Cancer Consortium, Partner Site Essen and University Alliance Ruhr, Research Center One Health, Essen, Germany., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Simeone E; Melanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola, 53, 80131, Naples, Italy., Ascierto PA; Melanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola, 53, 80131, Naples, Italy. paolo.ascierto@gmail.com.
Publikováno v:
Journal of translational medicine [J Transl Med] 2023 Oct 25; Vol. 21 (1), pp. 753. Date of Electronic Publication: 2023 Oct 25.
Autor:
Aoude LG; Frazer Institute, University of Queensland, Woolloongabba, Queensland. Electronic address: l.aoude@uq.edu.au., Brosda S; Frazer Institute, University of Queensland, Woolloongabba, Queensland., Ng J; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland., Lonie JM; Frazer Institute, University of Queensland, Woolloongabba, Queensland., Belle CJ; Frazer Institute, University of Queensland, Woolloongabba, Queensland., Patel K; Frazer Institute, University of Queensland, Woolloongabba, Queensland., Koufariotis LT; QIMR Berghofer Medical Research Institute, Herston, Queensland., Wood S; QIMR Berghofer Medical Research Institute, Herston, Queensland., Atkinson V; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland., Smithers BM; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland; Faculty of Medicine, University of Queensland, Herston, Queensland, Australia., Pearson JV; QIMR Berghofer Medical Research Institute, Herston, Queensland., Waddell N; QIMR Berghofer Medical Research Institute, Herston, Queensland., Barbour AP; Frazer Institute, University of Queensland, Woolloongabba, Queensland; Queensland Melanoma Project, Princess Alexandra Hospital, Woolloongabba, Queensland., Bonazzi VF; Frazer Institute, University of Queensland, Woolloongabba, Queensland. Electronic address: v.bonazzi@uq.edu.au.
Publikováno v:
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2023 Oct; Vol. 25 (10), pp. 771-781. Date of Electronic Publication: 2023 Aug 05.
Autor:
Larkin J; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Mandalá M; Papa Giovanni XIII Hospital, Bergamo, Italy., Gogas H; National and Kapodistrian University of Athens, Athens, Greece., Arance Fernandez AM; Hospital Clínic de Barcelona, Barcelona, Spain., Dalle S; Hospices Civils de Lyon, Pierre Bénite, France., Cowey CL; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas., Schenker M; Oncology Center Sf Nectarie Ltd., Craiova, Romania., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Chiarion-Sileni V; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Marquez-Rodas I; General University Hospital Gregorio Marañón and CIBERONC, Madrid, Spain., Butler MO; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., Middleton MR; Churchill Hospital, Oxford, United Kingdom., Lutzky J; Sylvester Comprehensive Cancer Center, Miami, Florida., de la Cruz-Merino L; Hospital Universitario Virgen Macarena, Clinical Oncology Department, University of Seville, Seville, Spain., Arenberger P; Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Atkinson V; Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia., Hill AG; Tasman Health Care, Southport, QLD, Australia., Fecher LA; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan., Millward M; University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia., Nathan PD; Mount Vernon Hospital, Middlesex, United Kingdom., Khushalani NI; H. Lee Moffitt Cancer Center, Tampa, Florida., Queirolo P; IEO, European Institute of Oncology IRCCS, Milan, Italy., Ritchings C; Bristol Myers Squibb, Princeton, New Jersey., Lobo M; Bristol Myers Squibb, Princeton, New Jersey., Askelson M; Bristol Myers Squibb, Princeton, New Jersey., Tang H; Bristol Myers Squibb, Princeton, New Jersey., Dolfi S; Bristol Myers Squibb, Princeton, New Jersey., Ascierto PA; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Weber J; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 01; Vol. 29 (17), pp. 3352-3361.
Autor:
Kennedy OJ; University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom; Christie NHS Foundation Trust, Manchester, Wilmslow Rd, Manchester M20 4BX, United Kingdom. Electronic address: ojk@doctors.org.uk., Kicinski M; EORTC Headquarters, Brussels, Belgium., Valpione S; Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, United Kingdom., Gandini S; Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Suciu S; EORTC Headquarters, Brussels, Belgium., Blank CU; Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Long GV; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Atkinson VG; Princess Alexandra Hospital, Brisbane, QLD, Australia., Dalle S; Hospices Civils de Lyon Cancer Institute, Lyon, France., Haydon AM; Alfred Hospital, Melbourne, VIC, Australia., Meshcheryakov A; NN Blokhin Cancer Research Center, Moscow, Russian Federation., Khattak A; Fiona Stanley Hospital & Edith Cowan University, Perth, WA, Australia., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia., Sandhu S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Larkin J; Royal Marsden Hospital, London, United Kingdom., Puig S; Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS, and Spain &Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain., Ascierto PA; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Schadendorf D; University Hospital Essen, Essen, German Cancer Consortium, Partner Site Essen & University Alliance Ruhr Research Center One Health, Essen, Germany., Boers-Sonderen M; Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands., Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., van den Eertwegh AJM; Amsterdam University Medical Center, location VUMC, Amsterdam, the Netherlands., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Gutzmer R; Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Minden, Germany., Jamal R; Centre Hospitalier de l'Université de Montréal (CHUM), Centre de recherche du CHUM, Montreal, QC, Canada., van Akkooi ACJ; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Robert C; Gustave Roussy and Paris-Saclay University, Villejuif, France., Eggermont AMM; Princess Máxima Center and University Medical Center Utrecht, 3584 CS Utrecht, the Netherlands; Comprehensive Cancer Center Munich, Technical University Munich & Ludwig Maximiliaan University, Munich, Germany., Lorigan P; Christie NHS Foundation Trust, Manchester, Wilmslow Rd, Manchester M20 4BX, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Mandala M; University of Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Aug; Vol. 189, pp. 112900. Date of Electronic Publication: 2023 Apr 29.
Autor:
Thompson JR; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia., Lai-Kwon J; Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia., Morton RL; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.; National Health and Medical Research Council Clinical Trials Center, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2050, Australia., Guminski AD; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.; Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, Australia., Gonzalez M; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia., Atkinson V; Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia.; Faculty of Medicine, University of Queensland, Brisbane, Queensland, 4072, Australia., Sandhu S; Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia., Brown MP; Translational Oncology Laboratory, Center for Cancer Biology, SA Pathology & University of South Australia, Adelaide, South Australia, 5001, Australia.; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, 5005, Australia., Menzies AM; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.; Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, Australia.; Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2006, Australia., McArthur GA; Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia., Lo SN; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.; Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2006, Australia., Long GV; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.; Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, Australia.; Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2006, Australia.; Charles Perkins Center, The University of Sydney, Sydney, New South Wales, 2006, Australia., Bartula I; Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia.
Publikováno v:
Immunotherapy [Immunotherapy] 2023 Jun; Vol. 15 (8), pp. 593-610. Date of Electronic Publication: 2023 May 02.